Table 1.
Characteristics of the study population
| Characteristic | DTG + 3TC (n = 257) | BIC/FTC/TAF (n = 268) | p |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 196 (76.3) | 236 (88.1) | < 0.001 |
| Female | 61 (23.7) | 32 (11.9) | |
| Age, median (IQR), year | 55 (38–68) | 36 (30–48) | < 0.001 |
| BMI, mean ± SD, kg/m2 | 22.2 ± 2.8 | 22.2 ± 2.9 | NS |
| Number of previous ART changes, median (IQR) | 1 (1–2) | 1 (1–2) | NS |
| Time from confirming HIV-1 to starting ART, median (IQR), days | 20 (9–15) | 22 (11–69) | NS |
| Time from confirming HIV-1 to replacement plan, median (IQR), years | 3 (1–6) | 4 (2–7) | NS |
| CD4+ cell count, cells/μL, n (%) | |||
| < 500 | 195 (75.9) | 178 (66.4) | 0.022 |
| ≥ 500 | 62 (24.1) | 90 (33.6) | |
| HIV-1 RNA, copies/mL, n (%) | |||
| < 50 | 219 (85.2) | 236 (88.1) | NS |
| ≥ 50 | 38 (14.8) | 32 (11.9) | |
| Previous ART, n (%) | |||
| 2NRTI + INSTIa | 132 (51.4) | 88 (32.8) | < 0.001 |
| 2NRTI + NNRTI | 93 (36.2) | 142 (53) | |
| Other | 32 (12.4) | 38 (14.2) | |
| Reason for dressing change: | |||
| Side effects of previous ART | 125 (48.6) | 77 (28.7) | < 0.001 |
| Patient’s own request | 50 (19.5) | 80 (29.8) | |
| Simplification/optimization | 32 (12.5) | 5 (1.9) | |
| Easy to take | 25 (9.7) | 76 (28.4) | |
| Low potential for interaction | 14 (5.5) | 7 (2.6) | |
| Reimbursement requirements | 6 (2.3) | 15 (5.6) | |
| Other | 5 (1.9) | 8 (3) | |
| Previous TDF-based regimen, n (%) | 161 (62.6) | 157 (58.6) | NS |
| Diabetes mellitus | 27 (10.5) | 4 (1.5) | < 0.001 |
| Hypertension | 39 (15.2) | 14 (5.2) | < 0.001 |
| AIDS-defining opportunistic illnesses | 25 (9.7) | 9 (3.3) | 0.005 |
ART antiretroviral therapy, INSTI integrase strand transfer inhibitor, NRTI nucleoside reverse transcriptase inhibitor, NNRTI non-nucleoside reverse-transcriptase inhibitor, PI protease inhibitor, BMI body mass index, NS no significant difference, TDF tenofovir disoproxil fumarate
aThe main regimen is TDF + 3TC + DTG